That is a good point that many don’t realize or consider. Whether they would be on leronlimab for a few years or the rest of their life isn’t clear to me at this point, but I would think for initial patient safety reasons, it would be until it was proven safe to be removed from treatment and no risk of increased CTCs or metastasis. I haven’t been calculating this (because even the annual numbers seem silly punching in the calculator), but is definitely a factor if cancer results are positive.

If I have time later today, I will try and put all these pieces together in a post for those here (RP stating either all cancers or a list of them that 50% over express CCR5 @ NC, US cancer stats, NP quote you reference, etc.). The market potential is enormous and if the cancer clinical results work, the “worldwide news” should definitely move the share price.